Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Technological platforms boost European cardiovascular research

13.12.2006
Proteomics, bioinformatics and Zebrafish are the novel tools set up by the European Vascular Genomics Network (EVGN).

Advanced technology is crucial to today’s biomedical research. But it is expensive and it requires specific expertise, which is expensive too. Then sharing becomes a must. And it guarantees a high level of cooperation among research groups throughout Europe. In 2006, the European Vascular Genomics Network (EVGN), a Network of Excellence funded by the European Union within its 6th Framework Programme, has launched three platforms, all of them representing cutting edge tools in the field of cardiovascular science and aimed at strengthening and improving the research effectiveness of the Network. The platforms were presented during the Third EVGN annual Conference (Toulouse, 11-14 December 2006).

The Zebrafish platform (Zebrafish, the fish Danio rerio, is an extremely versatile model organism in modern molecular biology) intends to provide EVGN scientists with a direct access to the Zebrafish model system for in vivo studies of cardiovascular development and disease. The Zebrafish platform is based at IFOM, the FIRC Institute of Molecular Oncology (Milan, Italy) and it is led by EVGN scientist Marina Mione.

The bioinformatics platform will provide EVGN researchers with a comprehensive set of software and web tools for storing, accessing, analyzing and elaborating the huge amount of data that comes from today’s high throughput technologies (in particular, gene and protein expression data). The platform is managed by Anton Horrevoets of the Academisch Medisch Centrum (University of Amsterdam).

Last but not least, an innovative proteomic platform has been launched, to perform advanced studies on structure and function of the proteins involved in the process of formation and development of cardiovascular disease. The promise of proteomics in this field is to carry out large scale-studies of gene expression at the protein level, providing the basis for a detailed understanding of pathophysiological mechanisms and leading to the discovery of potential targets for drug development. The EVGN proteomic platform is managed by Manuel Mayr, of the St George's Hospital Medical School (London, UK).

“EVGN platforms – explains EVGN scientific coordinator Alain Tedgui, of Inserm, Paris – represent essential tools to our network. These technologies are necessary for today’s research, but they are extremely expensive, and would not be affordable for individual institutes. Also, every platform requires specific and advanced expertise, and this is expensive too. Sharing human and technological resources becomes then crucial. Also, having common platforms guarantees that we all work with experts with both highly specific expertise and a solid background in cardiovascular disease.” More than being just core facilities, the EVGN platforms base their work on collaborative projects. “The scientists who work at the platforms – adds Tedgui – are not technicians, they are indeed involved in collaborative projects with several EVGN partners.”

The future of EVGN

EVGN, which was launched in 2004, will be active until the end of 2008. But its legacy will be taken on by new specific projects to be activated during the 7th Framework Programme. “What we have done here, with EVGN, was to lay the foundations of European vascular disease with a highly collaborative approach. Now we need to go on. Some of the area that will be covered by the new Programme – says Tedgui – will directly interest EVGN members. For example inflammatory and vascular remodelling, or stem cells in ischemic disease. Several groups and leaders of EVGN will join together and propose innovative actions in these fields of research.”

The European Vascular Genomics Network (EVGN) is the first Network of excellence on cardiovascular disease funded by the European Commission under the 6th Framework Programme "Life sciences, genomics and biotechnology for health" (Contract Number: LSHM-CT-2003-503254).

The Third EVGN Annual Conference is supported by an unrestricted educational grant from Laboratoires SERVIER.

Francesca Noceti | alfa
Further information:
http://www.ifom-ieo-campus.it
http://www.evgn.org

Further reports about: Cardiovascular EVGN expensive vascular disease

More articles from Life Sciences:

nachricht Scientists spin artificial silk from whey protein
24.01.2017 | Deutsches Elektronen-Synchrotron DESY

nachricht Choreographing the microRNA-target dance
24.01.2017 | UT Southwestern Medical Center

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists spin artificial silk from whey protein

X-ray study throws light on key process for production

A Swedish-German team of researchers has cleared up a key process for the artificial production of silk. With the help of the intense X-rays from DESY's...

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Breaking the optical bandwidth record of stable pulsed lasers

24.01.2017 | Physics and Astronomy

Choreographing the microRNA-target dance

24.01.2017 | Life Sciences

Spanish scientists create a 3-D bioprinter to print human skin

24.01.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>